Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc announces FDA approves ELOCTATE


Friday, 6 Jun 2014 04:46pm EDT 

Biogen Idec Inc:U.S. Food and Drug Administration (FDA) has approved ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A.ELOCTATE is recombinant hemophilia A therapy with prolonged circulation in body.It is treatment for hemophilia A to reduce frequency of bleeding episodes with prophylactic infusions every three to five days, offering people with hemophilia A the potential to extend the interval between prophylactic infusions. 

Company Quote

321.34
9.93 +3.19%
12:28pm EDT